retatrutide clinical trials status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical with anticipated completion in 2025–2026 and Triple hormone receptor agonist retatrutide

2.5mg is a therapeutic dose capable of producing meaningful weight loss, not a placebo starter

However, their benefits are typically sustained only while the medication is actively used

Nasal Spray Melanotan 2 Nasal Spray Synthetic alpha-MSH analog nasal spray, 6mg total, 80 sprays at 75mcg per spray

Hyaluronic acid Although not a collagen precursor, oral hyaluronic acid has been studied for its potential to support skin hydration and elasticity and is frequently combined with collagen ingredients

Retatrutide adds glucagon receptor activation on top of the GLP-1 and GIP effects

I will continue to use you going forward and recommend you to others